Spyre Therapeutics (SYRE) Invested Capital (2016 - 2025)
Historic Invested Capital for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $466.1 million.
- Spyre Therapeutics' Invested Capital rose 3237.16% to $466.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $466.1 million, marking a year-over-year increase of 3237.16%. This contributed to the annual value of $542.9 million for FY2024, which is 19280.82% up from last year.
- Spyre Therapeutics' Invested Capital amounted to $466.1 million in Q3 2025, which was up 3237.16% from $515.7 million recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Invested Capital registered a high of $542.9 million during Q4 2024, and its lowest value of -$237.9 million during Q3 2023.
- For the 5-year period, Spyre Therapeutics' Invested Capital averaged around $187.6 million, with its median value being $119.0 million (2021).
- Per our database at Business Quant, Spyre Therapeutics' Invested Capital tumbled by 45214.57% in 2023 and then skyrocketed by 97706.75% in 2024.
- Over the past 5 years, Spyre Therapeutics' Invested Capital (Quarter) stood at $83.9 million in 2021, then plummeted by 40.07% to $50.3 million in 2022, then surged by 268.56% to $185.4 million in 2023, then skyrocketed by 192.81% to $542.9 million in 2024, then decreased by 14.14% to $466.1 million in 2025.
- Its last three reported values are $466.1 million in Q3 2025, $515.7 million for Q2 2025, and $525.4 million during Q1 2025.